Shares to trade today: Trade Brains Portal recommends two shares for May 30

Copyright © HT Digital Streams Limit all rights reserved. Best Stocks To Buy Today: Trading Brains Portal recommends two shares for May 30 -Samplant Shares To Trade Today: Discover the Best Shares by Market Experts at Trading Portal for Friday, May 30. Indian stock markets recovered on Thursday after falling for two consecutive sessions. The BSE Sensex rose by 320.70 points (+0.39%) to close at 81,633.02, while the Nifty scored 50 81.15 points (+0.33%) to settle at 24,833,60. Today’s returns were broadly based, but more focused on Sectors affected by Trump rates, with the Nifty metal index leading the sectoral increase, by 1.21%. Shares to trade today as recommended by Trade Brains Portal Computer Age Management Services Ltd (Current Price: £ 3.987) Target Price: £ 4,960 in 16-24 months Stop Loss: £ 3,500 Why it is recommended: Computer Age Management Services Ltd. is a leading technology-driven financial infrastructure and services service services that have a dominant 68% market share in registrar and transfer agent (RTA). It mainly serves technology-driven solutions for mutual funds, AIFs and insurance companies. In FY25, their revenue from the mutual fund grew by 25%, and the transaction volume grew by 49% to 89.2 crore from 59.8 crore, and new SIP registrations rose by 51% to 400 lakh, and the growth of the SIP book stood at 5.7 crore, an 18% growth. Unique investors rose to 4.04 crore, by 26% higher, and live investor folios stood at 9.4 crore, a 30% growth -yoy. Furthermore, the shares of Aum grew 29% yoy to £ 24.8 trillion, with a market share of 66.1% and 86% growth in equity sales to £ 3.6 trillion years. Furthermore, the systematic transactions grew by 43% to 72.3 crore. Their revenue from non-mutual fund assets has grown by 25% year, and non-MF contains a variety of services such as Cams Pay, Cams alternatives, CAMS keepers, CAMS KRA, Cams Finserv, Think360 and CAMS NPS. In FY25, the non-mutual fund company had a strong revenue growth. For FY25, total turnover grew by 25% year to £ 1.475 crore of £ 1.177 crore in FY24, the Ebitda industry stood at £ 656 crore, a 46% jump, and Pat beat FY24 by 33% to £ 465. In addition, the company focuses on costs and expects it less than 10% for FY26. Ebitda margins for FY26 would be about 20% for non-MF and 44% for the mutual fund segment. On the CapeX side, the company expects £ 100 crore on architecture and £ 70 on Bau Capex, including regulatory air gap data centers and technical upgrades. In addition, with the net inflow of the mutual fund industry and market gain of £ 8.15 Lakh -Crore, the mutual fund sector in India achieved an increase of 23.11% in AUM, which reached £ 65.74 by March 2025. At the end of April 2025, the AUM stood at £ 69.99. It grew about six and a half in a ten -year period. Furthermore, debt funds had a revival, while stock-oriented schemes were the largest inflow of £ 4,17 Lakh-Crore. Folios rose 32% year to year to reach 23.45 crore, indicating an increase in investor involvement in all categories. Risk factor: Computer Age Management Services (CAMs) have a significant revenue concentration risk due to the heavy dependence on the Mutual Fund (MF) services segment, 73.2% of its total turnover, and more specifically on the top asset management company (AMC) customers. This concentration creates vulnerability: any regulatory, market or client-specific changes that affect the mutual fund industry, or these key customers can substantially affect CAMS’s financial performance. Also read: The Temperament Trap: Why Your Personality Your Portfolio’s Greatest Enemy Sun Pharmaceutical Industries Ltd (Current Price: £ 1,699) Target Price: £ 1.990 in 16-24 months Stop-loss: £ 1,553 Why it is recommended: Sun Pharma is the world’s leading specialty, generic and Consumer health products. The company is the largest pharmaceutical business in India and is a leading generic business in the US as well as in the global emerging markets. The company’s products are included in dermatology, ophthalmology and Onco-dermatology, which account for more than 18% of the company’s sales. Sun Pharma was distributed over 100 countries. In FY25, gross sales were £ 52,041.2 crore, a 9%growth. Ebitda stood at £ 15,271.7 crore, by 17.3% higher, and the net profit for FY25 was £ 11,984.4 crore, a 14% growth -yoy. The company’s total dividend for FY25 was £ 16 a share, and it announced a final dividend of £ 5.5 per share. In India, the formulation of £ 16,923 sales was a 14%increase. US formulation sales stood at $ 1.921 million, up 3.6%, and global specialty sales were at $ 1.216 million, with 17%. In emerging markets, sales of the formulation were at $ 1,114 million, by 7% higher, and the rest of the world’s formulation sales rose 4.5% to $ 847 million. Furthermore, the company increased its API by 11% to £ 2,129.2 crore, and external sales were at £ 533 for Q4 FY25, with 28%. At R&D, the company invested £ 3,248.4 for FY25, or 6.2% of sales, and the specialty -R & D pipeline contains 8 new entities in the clinical stage. The company received approval for 542 Andas in the US, and 117 filing for Andas awaits US approval. This includes 33 provisional approvals. In addition, the portfolio contains 57 approved NDAs, while 13 NDAs await the US -FDA approval. For the quarter, 9 andAs were submitted, and 1 ANDA approval was received. Global Speciality Pipeline, Ilumya, for psoriatic arthritis, is in phase 3, with the following milestone by H2CY25. Fibromun for soft tissue sarcoma and glioblastoma are in phase 3 and 2, and SCD-044 for atopic dermatitis and psoriasis is currently in phase 2 and will be reached during H1CY25. GL0034 for type 2 diabetes, completed starts during H2CY25, and MM-II for pain in osteoarthritis are completed, and plan to enter into a commercialization partnership. Risk factor: The pharmaceutical industry is strictly regulated, with strict guidelines of authorities such as the FDA; Non-compliance can lead to serious consequences, such as product memories and legal fines. Pharmaceutical businesses experience strong competition from both established firms and new entrants; Therefore, a lack of innovation or a limited product range can reduce the market share and loyalty of customers. Also read: Sun Pharma to increase the growth-reinforcing specialty portfolio in the FY26 market survey on Thursday, May 29, 2025, has recovered Indian stock markets after falling for two consecutive sessions. The BSE Sensex rose by 320.70 points (+0.39%) to close at 81,633.02, while the Nifty gained 50 with 81.15 points (+0.33%) to settle at 24,833,60. Today’s returns were broadly based, but more focused on Sectors affected by Trump rates, with the Nifty metal index leading the sectoral increase, by 1.21 percent. Welspun Corp rose 10 percent to the robust Q4 results. Other metal supplies, such as Tata steel, NMDC and Hindustan, also saw an uptick. The Nifty IT index also had a 0.76 percent increase. In contrast, the Nifty PSU bank fell 0.24 percent, and the defending FMCG index fell 0.13 percent on May 29, 2025 with the Indian markets. Japan’s Nikkei 225 closed 1.88 percent as Trump tariff relieved after the US court stopped the rates. Hong Kong’s Hang Seng index rose 1.35 percent, and China’s Shanghai composition also closed 0.70 percent, both after the US court suspension. The Indian market initially fell after it opened, but later closed to the global trend on the day’s peak, which was determined by the tariff suspension by the courts. Nifty 50 has been trying to break the 25,000 level since May 12. However, because of global uncertainty, the index still has to give a decisive exposition of the 25,000 level. Read also | Four fast growing space stocks to add to your Portal-Brain Portal of the Watchlist trading is a platform for stock analysis. The brand is Dailyraven Technologies Pvt. Ltd, and his SEBI registered registration number for research analysts are INH000015729. Investments in securities are subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI and NISM certification in no way guarantees the performance of the intermediary or gives any returns to investors. Disclaimer: The views and recommendations given in this article are those of individual analysts. This does not represent the views of coin. We advise investors to check with certified experts before making investment decisions. Catch all the business news, market news, news reports and latest news updates on Live Mint. Download the Mint News app to get daily market updates. More Topics #nifty 50 #Markets Premium #Sun Pharma Read Next Story